Human monoclonal antibodies against Hendra and Nipah viruses
AssigneesThe United States of America as represented by the Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsDimiter S. Dimitrov, Zhu Zhongyu, Christopher C. Broder
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
Claims16
An isolated antibody selectively binding a Hendra or Nipah G glycoprotein epitope wherein said antibody includes a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 307, CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 309, and CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 311, and a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 315, CDR2 region comprising SEQ ID NO:
- 317 and CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 319.
An isolated humanized antibody selectively binding a Hendra or Nipah G glycoprotein epitope, wherein said antibody includes:
- a) Heavy chain VH region comprising the amino acid sequence of SEQ ID NO:
- 305,
- b) Heavy chain FR1 region comprising the amino acid sequence of SEQ ID NO:
- 306,
- c) Heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 307,
- d) Heavy chain FR2 region comprising the amino acid sequence of SEQ ID NO:
- 308,
- e) Heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 309,
- f) Heavy chain FR3 region comprising the amino acid sequence of SEQ ID NO:
- 310,
- g) Heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 311,
- h) Heavy chain FR4 region comprising the amino acid sequence of SEQ ID NO:
- 312,
- i) Light chain VL region comprising the amino acid sequence of SEQ ID NO:
- 313,
- b) Light chain FR1 region comprising the amino acid sequence of SEQ ID NO:
- 314,
- c) Light y chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 315,
- d) Light y chain FR2 region comprising the amino acid sequence of SEQ ID NO:
- 316,
- e) Light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 317,
- f) Light chain FR3 region comprising the amino acid sequence of SEQ ID NO:
- 318,
- g) Light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 319, and
- h) Light chain FR4 region comprising the amino acid sequence of SEQ ID NO:
- 320.
Dependencies are inferred from the claim text.